SCHEMBL334483

SCHEMBL334483

CC(=O)c1ccc(O)c(CN2CCCCC2)c1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.67
PKM P14618 3/20 0.62
ALDH1A1 P00352 3/20 0.62
MEN1 O00255 1/20 0.62
KMT2A Q03164 1/20 0.62
TSHR P16473 3/20 0.60
HTT P42858 3/20 0.60
MAPT P10636 1/20 0.60
GFER P55789 1/20 0.59
CACNA1B Q00975 4/20 0.58
ACHE P22303 2/20 0.56
POLB P06746 1/20 0.50
HRH3 Q9Y5N1 2/20 0.49
ALPL P05186 1/20 0.49
ALPG P10696 1/20 0.49
GAA P10253 1/20 0.48
LMNA P02545 1/20 0.47
HPGD P15428 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13338348 0.88 TSHR (0.62) L3MBTL1PKMALDH1A1MEN1KMT2A
SCHEMBL16495328 0.88 TSHR (0.62) L3MBTL1PKMALDH1A1MEN1KMT2A
SCHEMBL2484395 0.88 TSHR (0.62) L3MBTL1PKMALDH1A1MEN1KMT2A
SCHEMBL4851304 0.87 PKM (0.55) L3MBTL1PKMALDH1A1MEN1KMT2A
SCHEMBL2485226 0.86 ACHE (0.61) L3MBTL1PKMALDH1A1MEN1KMT2A
SCHEMBL2483775 0.86 ACHE (0.61) L3MBTL1PKMALDH1A1MEN1KMT2A
SCHEMBL13338340 0.86 ACHE (0.61) L3MBTL1PKMALDH1A1MEN1KMT2A
SCHEMBL11619459 0.84 L3MBTL1 (0.65) L3MBTL1PKMALDH1A1MEN1KMT2A
SCHEMBL11619637 0.84 L3MBTL1 (0.65) L3MBTL1PKMALDH1A1MEN1KMT2A
Hydrochloric Acid SCHEMBL11619986 0.82 L3MBTL1 (0.67) L3MBTL1PKMALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
EP-1985620-A1 10a-AZALIDE COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2008-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 L3MBTL1 2853/4885PKM 4614/4885ALDH1A1 1939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.